1 reports of this reaction
3.3% of all LIDOCAINE HYDROCHLORIDE, MENTHOL reports
#3 most reported adverse reaction
CONSTIPATION is the #3 most commonly reported adverse reaction for LIDOCAINE HYDROCHLORIDE, MENTHOL, manufactured by ANI Pharmaceuticals, Inc.. There are 1 FDA adverse event reports linking LIDOCAINE HYDROCHLORIDE, MENTHOL to CONSTIPATION. This represents approximately 3.3% of all 30 adverse event reports for this drug.
Patients taking LIDOCAINE HYDROCHLORIDE, MENTHOL who experience constipation should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
CONSTIPATION is moderately reported among LIDOCAINE HYDROCHLORIDE, MENTHOL users, representing a notable but not dominant share of adverse events.
In addition to constipation, the following adverse reactions have been reported for LIDOCAINE HYDROCHLORIDE, MENTHOL:
The following drugs have also been linked to constipation in FDA adverse event reports:
CONSTIPATION has been reported as an adverse event in 1 FDA reports for LIDOCAINE HYDROCHLORIDE, MENTHOL. This does not prove causation, but indicates an association observed in post-market surveillance data.
CONSTIPATION accounts for approximately 3.3% of all adverse event reports for LIDOCAINE HYDROCHLORIDE, MENTHOL, making it one of the most commonly reported side effect.
If you experience constipation while taking LIDOCAINE HYDROCHLORIDE, MENTHOL, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.